Adaptimmune Therapeutics plc

NasdaqGS:ADAP Rapport sur les actions

Capitalisation boursière : US$204.5m

Adaptimmune Therapeutics Résultats passés

Passé contrôle des critères 0/6

Adaptimmune Therapeutics has been growing earnings at an average annual rate of 2%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 56.5% per year.

Informations clés

2.0%

Taux de croissance des bénéfices

14.9%

Taux de croissance du BPA

Biotechs Croissance de l'industrie17.0%
Taux de croissance des recettes56.5%
Rendement des fonds propres-75.3%
Marge nette-51.3%
Prochaine mise à jour des résultats13 Nov 2024

Mises à jour récentes des performances passées

Recent updates

The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Sep 26
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions

Sep 12

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024

Jul 03

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Apr 26

Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet

Apr 16
Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Feb 22
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Adaptimmune: Drug Approval Now Imminent?

Feb 02

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Dec 27
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts

Nov 09
News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Mar 08
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans

Feb 20
Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Nov 09
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Adaptimmune Therapeutics: Depressed Despite Upcoming BLA

Sep 20

We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Sep 15
We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022

Aug 10
Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022

Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics

Aug 03

Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022

Jun 29

Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA

Jun 19

Adaptimmune Therapeutics: A Little More Patience May Be Profitable

Mar 06

Circling Back On Adaptimmune Therapeutics

Dec 15

We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Dec 02
We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming

Sep 29

We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Aug 14
We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Adaptimmune Therapeutics: T-Cell Therapy Pioneer Boasts A Deep Pipeline, ESMO Approaches

Jul 29

Adaptimmune Therapeutics: Still The TCR Leader, And With Major Upcoming Catalysts

Jun 16

Adaptimmune Therapeutics (ADAP) Investor Presentation - Slideshow

Jun 05

Ventilation des recettes et des dépenses

Comment Adaptimmune Therapeutics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

NasdaqGS:ADAP Recettes, dépenses et bénéfices (USD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 24141-72790
31 Mar 2418-163770
31 Dec 2360-114720
30 Sep 2371-9561-67
30 Jun 2371-91610
31 Mar 2371-114590
31 Dec 2227-165610
30 Sep 2218-17563105
30 Jun 2212-176610
31 Mar 229-171600
31 Dec 216-158570
30 Sep 216-156560
30 Jun 216-149540
31 Mar 214-140500
31 Dec 204-130460
30 Sep 203-123430
30 Jun 202-127410
31 Mar 202-138410
31 Dec 191-137430
30 Sep 192-144430
30 Jun 1942-99430
31 Mar 1951-102440
31 Dec 1860-96440
30 Sep 1862-87420
30 Jun 1849-93390
31 Mar 1843-6936-19
31 Dec 1738-70310
30 Sep 1742-582917
30 Jun 1717-762632
31 Mar 1714-782468
31 Dec 1614-72230
30 Sep 1610-732363
30 Jun 1612-612157
31 Mar 1615-552148
31 Dec 1514-481840
30 Sep 1513-191429
30 Jun 1510-371024
31 Mar 157-16819
31 Dec 144-12516
30 Sep 142-13414
30 Jun 141-12310

Des revenus de qualité: ADAP is currently unprofitable.

Augmentation de la marge bénéficiaire: ADAP is currently unprofitable.


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: ADAP is unprofitable, but has reduced losses over the past 5 years at a rate of 2% per year.

Accélération de la croissance: Unable to compare ADAP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Bénéfices par rapport au secteur d'activité: ADAP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendement des fonds propres

ROE élevé: ADAP has a negative Return on Equity (-75.31%), as it is currently unprofitable.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé